SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001

OPKO Health said OPKO Biologics dosed the first participant in a Phase 1/2a trial of OPK-8801001 for acromegaly.

OPK

Related stories